ENTITY
WuXi AppTec

WuXi AppTec (2359 HK)

623
Analysis
Health Care • China
WuXi AppTec is a global contract research, development, and manufacturing organization (CRDMO) for the pharmaceutical and life sciences industries. It provides integrated, end-to-end services including chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services for various therapeutic modalities. The company was founded in 2000 and is headquartered in Shanghai, China.
more
bullish•WuXi AppTec
•28 Apr 2026 09:27•Broker

Quam Morning Note (28 Apr) - Wuxi AppTec

Wuxi Apptec reported a revenue increase of 28.8% y/y in 1Q26. Wuxi AppTec (2359 HK, NR) announced that it achieved total revenue of RMB12.44bn in...

Logo
142 Views
Share
bullish•WuXi AppTec
•26 Mar 2026 07:22•Broker

WuXi AppTec (603259 CH) - Strong CDMO Demand to Fuel 2026 Growth

WuXi AppTec reported impressive financial results for 2025, with revenue growing by 15.8% YoY (including 21.4% YoY growth for continuing...

Logo
146 Views
Share
bullish•WuXi AppTec
•24 Mar 2026 09:24•Broker

Quam Morning Note (24 Mar) - Wuxi Apptec

Hong Kong market commentary A-share market commentary Wuxi Apptec reported a revenue increase of 15.8% y/y in 2025

Logo
138 Views
Share
bullish•WuXi AppTec
•28 Oct 2025 20:38•Broker

WuXi AppTec (603259 CH) - Rising Demand for Small Molecule D&M Business

WuXi AppTec reported strong 3Q25 results, with revenue increasing by 15.3% YoY (including 19.7% YoY growth for continuing operations) and adj. non...

Logo
229 Views
Share
bullish•Shopify
•08 Oct 2026 11:01•Broker

KTX Tactical DR Picks

We recommend taking profits on WUXIAT80 with a 19.7% return, along with exiting positions in DDOG19 and NETO3, and cutting losses on BIREN23. We...

Logo
85 Views
Share
x